Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00903240
Other study ID # PBS-001
Secondary ID
Status Completed
Phase N/A
First received May 14, 2009
Last updated June 7, 2011
Start date May 2009
Est. completion date October 2010

Study information

Verified date November 2009
Source Predictive Biosciences
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

The purpose of this study is to detect recurrent bladder cancer using a combination of protein and DNA biomarkers in urine


Recruitment information / eligibility

Status Completed
Enrollment 1000
Est. completion date October 2010
Est. primary completion date April 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Intact bladder

- Scheduled for cystoscopy for transitional cell bladder cancer recurrence screening

- Urine donated prior to cystoscopy, Bladder biopsy, chemotherapy, intravesical therapy, radiation or TUR

- Must be willing to sign IRB approved informed consent

Exclusion Criteria:

- History or current diagnosis of any cancer except transitional cell bladder cancer or basal cell cancer

- Known diagnosis of any autoimmune disease or HIV, HCV or HBV

- History or current TB or any other active infection

- Subject has gross hematuria

- Receiving chemotherapy, intravesical therapy or radiation within 30 days of enrollment

- Any surgery except urologic within past 30 days

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Locations

Country Name City State
United States Associates in Urology/Urology Group of NJ 741 Northfield Avenue New Jersey
United States Capital Regional Urological Surgeons Albany New York
United States Community Care Physicians Albany New York
United States Coastal Urology Associates Brick New Jersey
United States The Urology Group Cincinnati Ohio
United States Urology Clinics of North Texas Dallas Texas
United States Atlantic Urological Associates Daytona Beach Florida
United States Urology Associates Engelwood Colorado
United States Metropolitan Urology Jeffersonville Indiana
United States Urological Associates of Lancaster Lancaster Pennsylvania
United States Carolina Urologic Research Center Myrtle Beach South Carolina
United States University Urology Associates New York New York
United States Winter Park Urology Orlando Florida
United States BCG Oncology Phoenix Arizona
United States Triangle Urologic Group Pittsburgh Pennsylvania
United States Hudson Valley Urology Poughkeepsie New York
United States Mayo Validation Support Services Rochester Minnesota
United States Urology San Antonio Research San Antonio Texas
United States Associated Medical Professionals Syracuse New York
United States Metro Urology Woodbury Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Predictive Biosciences

Country where clinical trial is conducted

United States,